Compare QUALCOMM, Inc. (QCOM) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
QUALCOMM, Inc. vs Twist Bioscience Corp — how do they compare? QUALCOMM, Inc. trades at $176.01 (market cap $185.94B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: QUALCOMM, Inc. is far larger — about 22.1× Twist Bioscience Corp's market cap, and QUALCOMM, Inc. pays a 2.11% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| QCOM | TWST | |
|---|---|---|
Market Cap | $185.94B | $8.42B |
Sector | Technology | Health |
52-Week High | $251.10 | $153.10 |
52-Week Low | $124.07 | $24.16 |
Enterprise Value | $192.90B | $8.35B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Qualcomm (QCOM) trades at $176.4, up 4.54% today, with a bullish technical signal from moving averages and oscillators. The company reported revenue of $44.28B in 2025, with a net income margin of 21.01%. Recent earnings show mixed results, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026. Analyst consensus is a Buy with a $200.56 price target, while news highlights AI and data center growth amid smartphone market challenges.
The outlook for QCOM is cautiously optimistic, driven by AI and data center expansion, but near-term risks include smartphone demand softness and margin pressures. Investment opportunity lies in diversification beyond handsets, though competition from Nvidia and Intel poses a threat. Earnings growth and execution on AI initiatives are key catalysts for upside.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
